- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06041620
자가 CRISPR-Cas12b 편집 조혈줄기세포의 안전성 및 유효성 평가
수혈 의존성 β 지중해빈혈 환자에서 자가 CRISPR-Cas12b 편집 조혈줄기세포의 효능과 안전성을 평가하기 위한 연구
This is a single-arm, open, single-injection exploratory clinical study with two transfusion-dependent β thalassemia (β-TDT) participants planned to enroll.
연구 개요
상세 설명
Through CRISPR-Cas 12b editing tool with independent intellectual property rights of Chinese Academy of Sciences, HBG1/2 promoter was edited to reactivate gamma-globin and induce fetal hemoglobin (HbF) expression. This leads to a subsequent reduction in ineffective red blood cell production (due to a reduction in the uncompounded alpha-globin chain) and improved red blood cell survival (due to reduced hemolysis), ultimately improving the sequelae of anemia and reducing the need for transfusion. Safety and efficacy will be evaluated continuously throughout the study, follow-up was up to 24 months. After the end of this trial, participants who received the infusion of autologous CRISPR-Cas12b edited hematopoietic stem cells (VGB-Ex01) will be invited to participate in the long-term follow-up study to complete the 15-year follow-up plan.
연구 유형
등록 (실제)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, 중국
- Regenerative Medicine Center
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Age 3-35 years old (inclusive), male or female;
- The subject and/or his/her legally recognized representative/parent/guardian fully understands the study and all information related to the study and has signed the informed consent form;
- Clinical diagnosis of transfusion-dependent β-thalassemia (TDT) with a blood transfusion record within 2 years (inclusive) prior to screening showing a history of ≥ 10 units (U)/kg/year (or ≥ 100 mL/kg/year) or ≥ 8 times/year of suspended RBC transfusions in at least 1 consecutive 12-month period;
- Karnofsky score (for subjects aged ≥ 16 years) or Lansky score (for subjects aged < 16 years) of ≥ 80;
- Subjects in stable disease state who are eligible for hematopoietic stem cell transplantation as per investigator's judgment;
- Access to diagnosis and treatment records issued by medical professional institutions within 2 years prior to screening, including the records of blood transfusions, hematology, serum chemistry, and other examinations;
- Willing and able to comply with study procedures, with good compliance, and willing to receive and complete the follow-up study with a duration of at least 2 years;
- Subjects of childbearing potential (including female subjects of childbearing potential and male subjects whose partners are of childbearing potential) must use effective contraception within 12 months of treatment.
Exclusion Criteria:
- Diagnosis of associated α-thalassemia: > 1 alpha chain deletion or alpha gene functional defect;
- Have available HLA-fully matched donors and acceptable for allogeneic hematopoietic stem cell transplantation;
- Irregular antibody or platelet antibody positive;
- Prior allogeneic bone marrow transplantation or gene therapy;
- Subjects with clinically significant and active bacterial, viral, fungal, or parasitic infection as determined by the investigator at screening, including but not limited to those with positive etiology of human immunodeficiency virus (HIV-1/2), human cytomegalovirus (HCMV-DNA), Epstein-Barr virus (EBV-DNA), or Treponema pallidum antibody (TP-Ab), or with previous hepatitis B or C infection;
- Subjects with an injury of major organs
- Contraindications for hematopoietic stem cell collection and poor collection efficiency judged by the investigator;
- Contraindications to the clinical investigational product and its excipients, G-CSF (hematopoietic stem cell mobilization), plerixafor (hematopoietic stem cell mobilization), busulfan (myeloablation), and other drugs;
- Participation within 3 months prior to screening or current participation in another interventional clinical study;
- History or family history of malignancy or myeloproliferative disorder;
- History of uncontrollable epilepsy, mental disorder, or other psychiatric disorders;
- Abuse of psychoactive substance, drug, or alcohol within 6 months prior to enrollment;
- Pregnant or breastfeeding females;
- Other diseases or reasons that interfere with study procedures;
- Any other conditions that the investigator deems unsuitable for the subject's participation in the study.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: VGB-Ex01
Each subject will accept one dose of VGB-Ex01. |
CRISPR-Cas12b editing hematopoietic stem cells |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Incidence of adverse events and serious adverse events
기간: Baseline up to 24 months
|
An adverse event is any untoward medical occurrence in a clinical investigation/participant administered a product; the event will not need to have a causal relationship with the treatment. A serious adverse event is any untoward medical occurrence at any dose that resulted in death; life threatening;require inpatient hospitalization or prolongation of existing hospitalization; result in persistent or significant disability/incapacity; result in congenital anomaly/birth defect. |
Baseline up to 24 months
|
|
Number of subjects with neutrophil implantation ≤ 42 days
기간: Baseline up to 42 days
|
Neutrophil implantation was defined as 3 consecutive days with 3 tests for ANC≥500/μL. |
Baseline up to 42 days
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Number of subjects transfusion independence (TI) for at least 6 months after transfusion
기간: Baseline up to 6 months
|
TI defined as Hb≥9g/dL without red blood cell infusion |
Baseline up to 6 months
|
|
Number of subjects transfusion independence (TI) for at least 12 months after transfusion
기간: Baseline up to 12 months
|
TI defined as Hb≥9g/dL without red blood cell infusion |
Baseline up to 12 months
|
|
Fetal hemoglobin (HbF) concentration
기간: Baseline up to 24 months
|
Changes in HbF concentration from baseline after transfusion |
Baseline up to 24 months
|
|
Total hemoglobin (Hb) concentration
기간: Baseline up to 24 months
|
Changes in Hb concentration compared with baseline after transfusion |
Baseline up to 24 months
|
|
The proportion of circulating red blood cells
기간: Baseline up to 24 months
|
Changes in the proportion of circulating red blood cells expressing fetal hemoglobin compared to baseline |
Baseline up to 24 months
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Jun Shi, PhD, Institute of Hematology & Blood Diseases Hospital, China
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- IIT2023048
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .